Calcitonin Side Effects: Safety Signals and Warnings
Calcitonin safety concerns are compound-specific. The main listed side effects are Nasal irritation and rhinitis (nasal spray), Nausea, and Facial flushing. The main warning signals are Potential small increased cancer risk with long-term use (EMA warning), Not recommended as first-line osteoporosis therapy - use bisphosphonates first, and Allergy testing recommended before first injection (salmon protein).
Direct Answer
Calcitonin (Miacalcin/Fortical) is FDA-approved for postmenopausal osteoporosis and Paget's disease, with decades of clinical data supporting its antiresorptive and analgesic effects. It is no longer considered a first-line osteoporosis agent - bisphosphonates and denosumab have superior fracture reduction data - but it retains approval and a valid evidence base. For calcitonin receptor pharmacology and pain modulation research, it is the reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Postmenopausal osteoporosis (second-line), Paget's disease, hypercalcemia of malignancy, bone pain modulation
Reported Side Effects
- Nasal irritation and rhinitis (nasal spray)
- Nausea
- Facial flushing
- Injection site reactions
- Diarrhea
- Urinary frequency
Warnings
- Potential small increased cancer risk with long-term use (EMA warning)
- Not recommended as first-line osteoporosis therapy - use bisphosphonates first
- Allergy testing recommended before first injection (salmon protein)
- Escape phenomenon - efficacy may wane with continuous use
- Nasal formulation requires intact nasal mucosa
Known or Plausible Interactions
- Bisphosphonates (may be used sequentially, not typically concomitantly)
- Lithium (calcitonin may reduce lithium levels)
- Prior bisphosphonate use may attenuate calcitonin response
Regulatory Context
FDA-approved for postmenopausal osteoporosis (when alternative treatments are unsuitable), Paget's disease of bone, and hypercalcemia. Available by prescription. Generic versions available. Restricted in EU to short-term use only.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Bone Pain Reduction (Level A), Osteoporosis Fracture Reduction (Level A), Paget's Disease Biochemical Response (Level A), and Cancer Risk Concern (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Calcitonin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/calcitonin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.